Although both the e13a2 and e14a2 subtypes code a p210 isoform, CML cases with the e13a2 subtype showed a poorer response to imatinib treatment than that with e14a2 subtypes [32,33,34]. The gene discussed is EVPL; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.